HIV treatment in Sweden
2010-12-23 - Pharmerit is pleased to announce their manuscript with the title "Cost-effectiveness of Atazanavir/r compared with Lopinavir/r in treatment-naďve HIV-1 patients in Sweden" has been published in the journal, “Scandinavian Journal of Infectious Diseases”.
Congratulations to Maarten Treur, Natalie Houwing, Bart Heeg, Marc Botteman, Ben van Hout and Abbott and AARDEX colleagues for receiving a Best Podium Award for their research titled: “A CONCEPTUAL FRAMEWORK THAT CAPTURES THE MULTI-DIMENSIONAL ASPECT OF ADHERENCE IN A HEALTH-ECONOMIC MODEL: AN APPLICATION IN CHRONIC NON-MALIGNANT PAIN MANAGEMENT” which was presented by Maarten Treur at the ISPOR 13th Annual European Congress on Monday November 8th 2010 at the Prague Congress Centre in Prague, Czech Republic.
Pharmerit researchers publish manuscript on indirect comparisons of second-generation tyrosine kinase inhibitors in chronic myelogenous leukemia
Pharmerit is pleased to announce their manuscript on indirect comparisons of second-generation tyrosine kinase inhibitors in CML has been published in the journal, “OncoTargets and Therapy”. The published study provides a case study example of second-line use of nilotinib and dasatinib for CML, followed by an overview of indirect comparison methods being increasingly used to address challenges with these types of comparisons. (link to pdf)
Pharmerit Staff to Present at American Society of Hematology Congress, Orlando, Florida US
2010-12-05 - Pharmerit staff members have prepared a research poster to be presented at the 2010 Annual Meeting of the American Society of Hematology on December 4-7 in Orlando, Florida. Presented as part of the myeloma session on the 5th of December, the poster is titled: "Optimal Treatment Sequencing In Mulyiple Myeloma: An Exploratory Modeling Approach".
Pharmerit researchers publish the cost-effectiveness of Risperdal Consta in Sweden
Pharmerit is pleased to announce that its cost-effectiveness research in schizophrenia has been published in the journal “Applied Health Economics and Health Policy”. The published study used a discrete event simulation model to compare the cost-effectiveness of long active risperidone and haloperidol depot in patients with schizophrenia, specifically in the subgroup of high risk non compliant patients.
Pharmerit Staff to Present Research at National Institutes of Health (NIH)’s International Conference on Outcomes Measurement
Dr. Ning Yan Gu, a Senior Scientist at Pharmerit International in Bethesda, MD is one of the speakers at the upcoming International Conference on Outcomes Measurement at the National Institutes of Health (NIH), which will be held in Natcher Conference Center on September 1-3 link.
Dr. Gu will discuss her research using latent trait analysis (Rasch models) to assess how selected health domains/items in a health-related quality-of-life (HRQoL) instrument underpin the instrument’s measurement strength and value. In her study, conducted as an extension of her doctoral research at the University of Southern California (USC), Dr. Gu used the EQ-5D—one of the most widely used preference-based HRQoL instruments—to illustrate how its health items’ goodness-of-fit to the latent construct of HRQoL relates to different diseases. She also investigated the quantitative improvement associated with the inclusion alongside of the EQ-5D of an adjective rating scale for summary measures of health. In addition, utilizing the parameter separation feature of the Rasch model, Dr. Gu demonstrated how the strength of the HRQoL measures can be dissected into those attributed to persons and those attributed to health items, analyzed along a common latent continuum. Such an approach has its unique and useful positions in both economic and clinical evaluations on patients’ responses to health care interventions, assessed on different health items. Dr. Gu’s use of latent trait theory allows for a more individualized approach to the use of HRQoL measures, which results in improved patient diagnosis, optimized allocation of patients to treatments, and enhanced monitoring of the performance of any health instruments. All of these improvements can contribute to better clinical decision making, improved clinical trial design, and more cost effective health care decisions.
Dipen Patel, BPharm, PhD Joins Pharmerit as Health Economist
Pharmerit is pleased to announce that Dr. Dipen Patel, PhD has joined its US office in Bethesda.
Phillip Wiegand, Pharm.D, MS, Joins Pharmerit as Market Access Manager
Pharmerit is pleased to announce that Phillip Wiegand, Pharm.D., MS has joined its Bethesda, MD team.
Pharmerit Staff Recognized for Excellence in Research
Ning Yan Gu , PhD, Senior Scientist at Pharmerit in Bethesda, MD, was the recipient of the Best New Investigator Podium Research Presentations Award at the ISPOR 15th Annual International Meeting. The title of her work was “Evaluating the measurement properties of an augmented EQ-5D with the inclusion of two single quality-of-life (QOL) indicators using the medical expenditure panel survey (MEPS).” (link) This research was conducted with co-authors Trevor G Bond from James Cook University, Townsville, QLD, Australia, and Ben M Craig, PhD, from Moffitt Cancer Center, Tampa, FL, USA. This presentation recognizes Dr Gu’s research to evaluated the measurement properties of the EQ-5D. This award comes as the fourth ISPOR best podium/poster presentations awarded to Dr Gu (she has been the recipient of the Best Student Podium Research Presentation Award in 2007 and 2008 and, the recipient of the Best Student Poster Research Presentation Award in 2009)
Please join us in congratulating Ning and Cailtyn and their respective co-authors for their excellence in research.
Pharmerit researchers publish the first Bayesian meta-analysis in MRSA skin and soft tissue infections
Pharmerit is pleased to announce that its comparative effectiveness research in methicillin-resistant staph aureus (MRSA) complicated skin and soft tissue infections (cSSTI) has been published in Current Medical Research and Opinion. This study used a Bayesian approach to compare success rates of six different antibiotics for MRSA cSSTI to inform HTA and formulary decision-making.
Caitlyn T. Wilke, M.S., Ph.D. Candidate is Joining Pharmerit
Pharmerit is pleased to announce that Caitlyn Wilke is joining its growing team. She will be based in the Bethesda, MD office.
Caitlyn will work closely with Pharmerit sponsors to help them address the many challenges to successful commercialization that exist in today's competitive healthcare market.
The Journal of Mental Health Policy and Economics publishes research in insomnia and comorbid major depressive disorder
Pharmerit is pleased to announce that its most recent research in insomnia and comorbid major depressive disorder (MDD) has been published in the The Journal of Mental Health Policy and Economics. The purpose of this analysis was to examine the costs and benefits of eszopiclone co-administered with fluoxetine compared to placebo co-administered with fluoxetine in adults meeting the DSM-IV criteria for insomnia and MDD. The results show that co-treatment resulted in net increases of 0.0058 QALYs and $81, leading to an incremental cost per QALY gained of approximately $14,000. Co-administration of eszopiclone and fluoxetine improved patients' insomnia symptoms and appeared to be a cost-effective treatment strategy for patients with insomnia and comorbid MDD. The publication can be found here. This study adds to the limited number of studies that evaluate the economic impact of insomnia in comorbid depression and it is the first cost effectiveness of this kind in this area. For more details about this study, please do not hesitate to contact co-authors Sonya Snedecor (;Tel: +1 240 821-1268) or Marc Botteman (;Tel: +1 240 821-1289).
New colleagues at Pharmerit NL
We are very pleased to announce that our international team has expanded with 3 new colleagues. Vân Bui, Marielle Tergau and Loes van Erp have joined the Pharmerit team in the Netherlands in the respective positions of Junior Research Consultant, Business Intelligence & Communication Specialist and Junior Business Development Manager. We are delighted to have them on board!
Current Medical Research and Opinion publishes Pharmerit research in ST-segment elevation myocardial infarction (STEMI)
Pharmerit is pleased to inform that its research in STEMI has been published in Current Medical Research and Opinion. This study assesses the costs and effects of combination treatment with clopidogrel and aspirin in comparison to aspirin alone in patients with an ST-segment elevation myocardial infarction (STEMI) in a Dutch setting (link to pdf).
Annals of Oncology publishes Pharmerit research in oncology
Pharmerit is pleased to inform that its research in oncology has been electronically published in Annals of Oncology. This analysis assessed the cost-effectiveness of Zoledronic acid for prevention of fractures in postmenopausal women with breast cancer.